Abu Bakar H Bhatti1, Faisal S Dar1, Muhammad O Butt2, Eraj Sahaab1, Mohammad Salih2, Najmul H Shah2, Nusrat Y Khan1, Haseeb H Zia1, Eitzaz U Khan3, Nasir A Khan3. 1. Department of HPB Surgery and Liver Transplantation, Shifa International Hospital, Sector H-8/4, Pitras Bukhari Road, Islamabad, Pakistan. 2. Department of Hepatology, Shifa International Hospital, Sector H-8/4, Pitras Bukhari Road, Islamabad, Pakistan. 3. Department of Anesthesiology, Shifa International Hospital, Sector H-8/4, Pitras Bukhari Road, Islamabad, Pakistan.
Abstract
BACKGROUND: The European association for the study of the liver and chronic liver failure consortium (EASL-CLIF) recently proposed diagnostic criteria for acute on chronic liver failure (ACLF). There is lack of data regarding liver transplant outcomes in ACLF patients based on these criteria. The objective of this study was to determine outcome following living donor liver transplantation (LDLT) in ACLF patients. METHODS: We retrospectively reviewed patients who underwent LDLT for ACLF based on European association for the study of the liver and chronic liver failure consortium (EASL-CLIF) diagnostic criteria (group 1) (N = 60) and compared them with ACLF patients who did not undergo transplantation (group 2) (N = 59). The primary outcome of interest was 30 day mortality. We also looked at one year survival in these patients. Survival was calculated using Kaplan-Meier curves and Log rank test was used to determine significance between variables. RESULTS: Median MELD scores for group 1 and 2 patients in ACLF grade 1 was 28 (20-38) and 31 (24-36), in ACLF grade 2 was 35 (24-42) and 36 (24-42) and in ACLF grade 3 was 36 (29-42) and 38 (32-52). For group 1 and 2, 30 day mortality in ACLF grade 1, 2 and 3 was 2/43(4.6%) versus 9/15(60%) (P < 0.001), 1/15 (6.6%) versus 13/19 (68.4%), 0/2 (0%) versus 20/25 (80%) (P < 0.001). Actuarial 1 year overall survival was 92% versus 11% (P < 0.001) in patients who underwent transplantation versus those who did not. One year survival in patients with grade 1 and 2 ACLF who received transplant versus medical treatment was 91% versus 13% and 93% versus 15% (P < 0.001) respectively. CONCLUSION: LDLT has excellent outcomes in patients with EASL-CLIF grade 1 and 2 ACLF. Without transplantation, ACLF patients have a very poor prognosis.
BACKGROUND: The European association for the study of the liver and chronic liver failure consortium (EASL-CLIF) recently proposed diagnostic criteria for acute on chronic liver failure (ACLF). There is lack of data regarding liver transplant outcomes in ACLF patients based on these criteria. The objective of this study was to determine outcome following living donor liver transplantation (LDLT) in ACLF patients. METHODS: We retrospectively reviewed patients who underwent LDLT for ACLF based on European association for the study of the liver and chronic liver failure consortium (EASL-CLIF) diagnostic criteria (group 1) (N = 60) and compared them with ACLF patients who did not undergo transplantation (group 2) (N = 59). The primary outcome of interest was 30 day mortality. We also looked at one year survival in these patients. Survival was calculated using Kaplan-Meier curves and Log rank test was used to determine significance between variables. RESULTS: Median MELD scores for group 1 and 2 patients in ACLF grade 1 was 28 (20-38) and 31 (24-36), in ACLF grade 2 was 35 (24-42) and 36 (24-42) and in ACLF grade 3 was 36 (29-42) and 38 (32-52). For group 1 and 2, 30 day mortality in ACLF grade 1, 2 and 3 was 2/43(4.6%) versus 9/15(60%) (P < 0.001), 1/15 (6.6%) versus 13/19 (68.4%), 0/2 (0%) versus 20/25 (80%) (P < 0.001). Actuarial 1 year overall survival was 92% versus 11% (P < 0.001) in patients who underwent transplantation versus those who did not. One year survival in patients with grade 1 and 2 ACLF who received transplant versus medical treatment was 91% versus 13% and 93% versus 15% (P < 0.001) respectively. CONCLUSION: LDLT has excellent outcomes in patients with EASL-CLIF grade 1 and 2 ACLF. Without transplantation, ACLF patients have a very poor prognosis.
Entities:
Keywords:
ACLF, acute on chronic liver failure; ACR, acute cellular rejection; CIT, cold ischemia time; EAD, early allograft dysfunction; EASL-CLIF, European Association for the Study of the Liver-Chronic Liver Failure; HCV, hepatitis C virus; HOTA, human organ transplantation authority; LDLT, living donor liver transplantation; LT, liver transplantation; MELD, model for end-stage liver disease; MHV, middle hepatic vein; OS, overall survival; WIT, warm ischemia time; liver failure; living transplantation; morbidity; mortality; survival
Authors: Thierry Gustot; Javier Fernandez; Elisabet Garcia; Filippo Morando; Paolo Caraceni; Carlo Alessandria; Wim Laleman; Jonel Trebicka; Laure Elkrief; Corinna Hopf; Pablo Solís-Munoz; Faouzi Saliba; Stefan Zeuzem; Augustin Albillos; Daniel Benten; José Luis Montero-Alvarez; Maria Teresa Chivas; Mar Concepción; Juan Córdoba; Aiden McCormick; Rudolf Stauber; Wolfgang Vogel; Andrea de Gottardi; Tania M Welzel; Marco Domenicali; Alessandro Risso; Julia Wendon; Carme Deulofeu; Paolo Angeli; François Durand; Marco Pavesi; Alexander Gerbes; Rajiv Jalan; Richard Moreau; Pere Ginés; Mauro Bernardi; Vicente Arroyo Journal: Hepatology Date: 2015-05-29 Impact factor: 17.425
Authors: Kim M Olthoff; Laura Kulik; Benjamin Samstein; Mary Kaminski; Michael Abecassis; Jean Emond; Abraham Shaked; Jason D Christie Journal: Liver Transpl Date: 2010-08 Impact factor: 5.799
Authors: Richard Moreau; Rajiv Jalan; Pere Gines; Marco Pavesi; Paolo Angeli; Juan Cordoba; Francois Durand; Thierry Gustot; Faouzi Saliba; Marco Domenicali; Alexander Gerbes; Julia Wendon; Carlo Alessandria; Wim Laleman; Stefan Zeuzem; Jonel Trebicka; Mauro Bernardi; Vicente Arroyo Journal: Gastroenterology Date: 2013-03-06 Impact factor: 22.682
Authors: Albert C Chan; Sheung Tat Fan; Chung Mau Lo; Chi Leung Liu; See Ching Chan; Kelvin K Ng; Boon Hun Yong; Alexander Chiu; Banny K Lam Journal: Hepatol Int Date: 2009-08-13 Impact factor: 6.047
Authors: Constantine J Karvellas; Thomas Lescot; Peter Goldberg; Michael D Sharpe; Juan J Ronco; Eberhard L Renner; Hina Vahidy; Zafrina Poonja; Prosanto Chaudhury; Norman M Kneteman; Markus Selzner; Earl F Cook; Sean M Bagshaw Journal: Crit Care Date: 2013-02-09 Impact factor: 9.097